English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Since viral-specific immunity has been shown to be correlated with viral containment in solid organ transplant recipients, we investigated an association of BK polyomavirus (BKPyV)-specific immunity and BKPyV viruria in kidney transplant (KT) recipients. Methods A prospective cohort study of all adult KT recipients between January and August 2019 was conducted. High-level BKPyV viruria was defined as the presence of BKPyV viral load in urine &amp;gt; 7log10 copies/mL. BKPyV-specific immunity was measured by an intracellular cytokine assay measuring the percentage of IFN-γ-producing CD4+, CD8+, NK, and NKT cells, after stimulation with large-T antigen (LT) and viral capsid protein 1 (VP1). The incidence of high-level BKPyV viruria within 6 months after KT was estimated by the Kaplan-Meier method. Clinical and immunological factors were analyzed using Cox proportional hazard model. BKPyV-specific immune responses prior to and at 1 month after KT were compared using a mixed-linear regression test. Results Among 90 evaluable patients, 37% were female with a mean age + SD of 42 + 12 years. Sixty-four and 68 % received deceased-donor KT and induction immunosuppressive therapy, respectively. The cumulative incidence of BKPyV viruria within 6 months was 20%. In multivariate analysis, pre-transplant factors which were independently associated with BKPyV viruria were panel-reactive antibody of 11-50 % (HR 13.35; 95%CI, 1.926-92.590; P = 0.009), %natural killer (NK) cells (HR 1.26; 95%CI, 1.077-1.469; P = 0.004), and %VP1-specific NK cells (HR 1.25; 95%CI, 1.088-1.433; P = 0.002). Among those with BKPyV viruria, the mean %NK, %VP1-specific NK cells and %NKT cells at 1-month post-KT were significantly increased over time as compared to pre-KT (coefficient: 1.202; 95%CI, 0.033-2.371; P = 0.04), (coefficient: 2.602; 95%CI, 1.083-4.121; P = 0.001), and (coefficient: 0.199; 95%CI, 0.051-0.348; P = 0.008), respectively. Conclusion A presence and increasing proportion of NK, VP1-specific NK and NKT cells were observed among KT recipients who developed early and clinically significant BKPyV viruria in our cohort. Quantification of BKPyV-specific NK and NKT cell immune monitoring could potentially stratify those at risk of BKPyV viruria among KT recipients. Disclosures All Authors: No reported disclosures

open forum infectious diseases

1189. Correlation of BK polyomavirus (BKPyV)-specific Immunity and BKPyV Viruria within 6 months after Kidney Transplantation: A Prospective Cohort Study